FDA Approves VABRINTY — URONOVA PHARMACEUTICALS, INC.

Uronova Pharmaceuticals announced the FDA approval of VABRINTY (Leuprolide Acetate) Subcutaneous for Autoinjector, continuing the company’s strategy of commercializing established oncology generics amid strengthening market demand. This approval, originally granted to Takeda Pharmaceutical in 2002, allows Uronova to offer a user-friendly subcutaneous alternative to traditional IV formulations, potentially capturing significant share in the prostate cancer and endometriosis sectors.